Lymph node biopsy in resource-limited breast cancer systems: a scoping review of non-nuclear mapping, implementation and outcomes

Hridhay Somera

doi:10.18203/2349-2902.isj20263877

Authors

Hridhay Somera Department of General Surgery, Victoria Mxenge Hospital, Durban, South Africa

DOI:

https://doi.org/10.18203/2349-2902.isj20263877

Keywords:

Breast cancer, Sentinel lymph node biopsy, Resource-limited settings, Methylene blue, Implementation science

Abstract

This study aimed to map non-nuclear sentinel lymph node biopsy techniques for breast cancer in resource-limited systems and synthesise implementation requirements and outcomes. Scoping review following Joanna Briggs Institute guidance and PRISMA-ScR. Setting: Services meeting a service-level definition of resource limitation; low- or middle-income country location alone was insufficient. Information sources: PubMed, Europe PMC and backward citation searching. Subjects: Clinical studies, implementation reports, surveys, reviews and guidelines on axillary staging. Outcome measures: Identification, false-negative performance, morbidity, axillary dissection avoided, cost, barriers and training. The merged database exports contained 2,301 records; 1,252 unique records were screened and 36 evidence sources included. Methylene blue (MB) programmes reported 85.7%–100% identification, with a 13% false-negative rate in one meta-analysis. Fluorescein plus MB achieved 82%–100% identification with false-negative rates of 6.3%–8.7%. Indocyanine green series achieved 95.7%–100% identification but required near-infrared equipment. Gentian violet achieved 97.5% identification in a small cohort. Ethiopian programmes achieved 100% identification; one avoided axillary dissection in 80%. North African data showed less lymphoedema after sentinel biopsy than dissection (3.8% versus 23.0%). Constraints were nuclear medicine, pathology, supply, training and follow-up. Non-nuclear sentinel node biopsy appears feasible in resource-limited services when introduced as a governed pathway rather than dye substitution. MB was the lowest-cost/lowest-infrastructure option identified; fluorescein plus MB adds redundancy, while indocyanine green suits services able to support reusable imaging. Evidence is insufficient to establish oncological equivalence. Prospective implementation studies with audited recurrence, morbidity and cost are required.

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I. Stage at diagnosis of breast cancer in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2016;4(12).

Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927-33.

Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599-609.

Yadav SK, Sharma D, Sharma DB, Kintu-Luwaga R, Jha CK, Shekhar S. Barriers and challenges in providing standard breast cancer care in low resource settings. Trop Doct. 2022;52(4):532-7.

El Saghir NS, El Tomb PA, Carlson RW. Breast cancer diagnosis and treatment in low- and mid-resource settings: the role of resource-stratified clinical practice guidelines. Curr Breast Cancer Rep. 2018;10(3):187-95.

Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467-73.

Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119-26.

Li J, Chen X, Qi M, Li Y. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2018;13(9).

Okoye CL, Ezeome ER. Use of methylene blue dye for lymphatic basin mapping and sentinel lymph node biopsy in breast cancer patients in Enugu, Nigeria. Niger J Clin Pract. 2022;25(11):1805-11.

Devarakonda S, Thomas SS, Sen S, Thomas V, Karuppusami R, Cherian AJ, et al. Sentinel lymph node biopsy in early breast cancer using methylene blue dye alone: a safe, simple, and cost-effective procedure in resource-constrained settings. Indian J Surg Oncol. 2021;12:210-17.

Hermansyah D, Rahayu Y, Azrah A, Pricilia G, Paramita D, Siregar ES, et al. Accuracy of methylene blue test as single technique for sentinel lymph node biopsy in early stages breast cancer. Asian Pac J Cancer Prev. 2021;22(9):2765-9

Getu Bekele P, Saha S, Thomas Malore E, Girma Mamo M, Demelash Gizachew S, Jemberu Robele T, et al. Preliminary results of sentinel lymph node biopsy using blue dye for early breast cancer staging: a single-centre experience in Addis Ababa, Ethiopia. East Cent Afr J Surg. 2024;29(1):16-22

Suga Y, Teklewold B, Ariaya A, Shimeles R, Jibril A. Feasibility of sentinel lymph node biopsy in a resource limited setting: an initial experience from Ethiopia. Ethiop J Health Sci. 2026;36(2):113-7.

Brand NR, Wasike R, Makhdomi K, et al. Sentinel lymph node biopsy pathology and 2-year postsurgical recurrence of breast cancer in Kenyan women. J Glob Oncol. 2018;4:1-7.

Yousef M, Roodt L, Masu A, Nel D, Malherbe F. Sentinel lymph node biopsy in a resource-limited setting: a retrospective comparison of sentinel lymph node biopsy before and after the introduction of Sentimag at an academic breast unit. S Afr J Surg. 2023;61(2):91-5.

Belkhodja A, Chiba Y, Zaabar L, Jaafar W, Malak M, Bouassida M, et al. Sentinel lymph node biopsy for breast cancer in North Africa: a retrospective analysis of feasibility, safety, and morbidity reduction in a real-world setting. Eur J Breast Health. 2026;22(1):61-5.

Seenu V, Suhani S, Srivastava A, Parshad R, Mathur S, Kumar R. Optimization of sentinel lymph node identification techniques in the Indian setting: a randomized clinical trial. Indian J Cancer. 2019;56(2):114-8.

Valiveru RC, Agarwal G, Agrawal V, Gambhir S, Mayilvaganan S, Chand G, et al. Low-cost fluorescein as an alternative to radio-colloid for sentinel lymph node biopsy—a prospective validation study in early breast cancer. World J Surg. 2020;44:3417-22.

Khadka S, Suresh J, Prem A, Mishra PR, Kataria K, Dhar A, et al. Sentinel node mapping in early breast cancer: a randomized comparison of fluorescein guided All India Institute of Medical Sciences, Anurag's technique with technetium-99m sulfur colloid plus methylene blue. Indian J Nucl Med. 2022;37(3):236-44.

Chavda J, Mishra A, Silodia A, Yadav SK, Sharma DB, Sharma D, et al. Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings. Breast Cancer Res Treat. 2022;193:105-10

Sethi RS, Kaur N, Patni S, Sharma P, Sharma A, Hussaini SS. Combined fluorescein and methylene blue dye for sentinel lymph node biopsy in patients of early carcinoma breast: a promising technique. Indian J Surg Oncol. 2024;15(4):891-900.

Gupta P, Agarwal VK, Varshney AK. Assessment of sensitivity of low-cost fluorescein as an alternative to radiocolloid for sentinel lymph node biopsy in breast carcinoma. Rep Pract Oncol Radiother. 2026;31(1):50-8.

Suhani, Kumar U, Seenu V, Sodhi J, Joshi M, Bhattacharjee HK, et al. Evaluation of dual dye technique for sentinel lymph node biopsy in breast cancer: two-arm open-label parallel design non-inferiority randomized controlled trial. World J Surg. 2023;47:2178-85.

Agrawal SK, Hashlamoun I, Karki B, Sharma A, Arun I, Ahmed R. Diagnostic performance of indocyanine green plus methylene blue versus radioisotope plus methylene blue dye method for sentinel lymph node biopsy in node-negative early breast cancer. JCO Glob Oncol. 2020;6:1225-31.

Somashekhar SP, Kumar CR, Ashwin KR, et al. Can low-cost indocyanine green fluorescence technique for sentinel lymph node biopsy replace dual dye (radio-colloid and blue dye) technique in early breast cancer: a prospective two-arm comparative study. Clin Breast Cancer. 2020;20(5).

Hidar S, Alimi A, Khlifi A, Chachia S, Kaabia O, Bouguizane S, et al. Indocyanine green fluorescence-guided sentinel node biopsy in breast cancer within a North African population: a retrospective study. Eur J Breast Health. 2021;17(4):352-5.

Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017;22(1):11-7.

Mooghal M, Ali ZM, Saleem L, Yaqoob A, Ahmad F, Jamal A. Evaluating gentian violet as a low-cost alternative for sentinel lymph node biopsy in breast cancer: a single-center retrospective study. Asia Pac J Clin Oncol. 2026.

Park B, Han M, Park J, Kim T, Ryu H, Seo Y, et al. A photoacoustic finder fully integrated with a solid-state dye laser and transparent ultrasound transducer. Photoacoustics. 2021;23:100290.

Han M, Lee YJ, Ahn J, et al. A clinical feasibility study of a photoacoustic finder for sentinel lymph node biopsy in breast cancer patients: a prospective cross-sectional study. Photoacoustics. 2025;43:100716.

Yadav SK, Garg G, Baderiya D, et al. BRIDGEing the gap: impact of a short virtual course on delivering global-standard breast cancer care in low-resource settings. World J Surg. 2026;50(2):385-92.

Yadav SK, Nema M, Sharma DB, Agarwal P, Sharma D. Mastering low-cost sentinel lymph node biopsy using fluorescein sodium and methylene blue dye: evaluating its learning curve in breast cancer surgery. Indian J Surg Oncol. 2026;17(6):1435-9.

Bandaranayake V, Nellihela AP, Asanthi J, et al. Outcomes of methylene blue single-dye sentinel lymph node biopsy in early breast cancer: a retrospective cohort study from a resource-limited tertiary centre. Research Square [Preprint]. 2026.

Ratnagiri R, Srivastava MK, Uppin MS, et al. Performing sentinel lymph node biopsy without a hand-held gamma probe—overcoming hurdles through teamwork: an analysis of our learning curve over five years. World J Surg Oncol. 2025;23(1):285.

Buccimazza I. Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities. World J Surg. 2011;35(6):1155-8.

Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries. Cancer. 2008;113(8 Suppl):2221-43.

Park KU, Somerfield MR, Anne N, Brackstone M, Conlin AK, Couto HL, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43(14):1720-41.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918-26.

Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41(12):2159-65.